PCAS : STRENGTHENS ITS FOOTHOLD IN PHARMACEUTICALS IN NORTH AMERICA

 PCAS makes changes in its Canadian site to develop
a pharmaceutical activities

The FDA confirms its approval for the PCAS site in Finland

Longjumeau, June 9, 2015, PCAS (Euronext Paris: PCA), expert in the development and production of complex molecules for life sciences and innovative technologies, is developing a pharmaceutical activity at its Canadian site of St-Jean-sur-Richelieu, in the south of Montreal (Quebec).

This change is in line with the Group's strategy aimed at consolidating its pharmaceutical activity in North America. Given its high-level expertise in R&D and its proximity to the biotech and medtech centers in and around Boston, the St-Jean-sur-Richelieu site in Canada has all the assets needed to strengthen its links with companies in this industry and develop the Health business while continuing its micro-electronics activity.

This change is also a legal and organizational one; the St-Jean Photochimie site has amended its articles of association to change its name: SJPC is now PCAS Canada Inc.

Mr Vincent Touraille, Chief Executive Officer of PCAS comments: "This change is fully in line with our development strategy, namely to focus on growth segments and areas with high added value. In this respect our Canadian site is ideally placed, by virtue of its proximity to the biotech and medtech companies on the east coast of the United States. "

America is a key market for the group, whose customer portfolio already includes laboratories such as Pfizer, Abbott and Gilead.

Among the Group's cGMP sites serving this market, the PCAS site at Turku in Finland secured the renewal of its FDA approval in May, without any observations, which illustrates PCAS's total commitment to quality. The site regularly produces 14 active ingredients for the American market, without taking into account products currently being launched.

Next financial disclosure:
Half-year sales, 28 July 2015

PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €166 million in 2014 and employs nearly 900 people in six countries.
To find out more about PCAS, visit www.pcas.com:
http://www.pcas.com.